Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade

摘要: The majority of individuals exposed to hepatitis C virus (HCV) establish a persistent infection, which is leading cause chronic liver disease, cirrhosis and hepatocellular carcinoma. Major progress has been made during the past twenty-five years in understanding HCV life cycle immune responses against infection. Increasing evidence indicates that host genetic factors can significantly influence outcome infection response interferon alpha-based antiviral therapy. arrival highly effective convenient treatment regimens for patients chronically infected with improved prospects eradication worldwide. Clinical trials are evaluating best anti-viral drug combination, doses duration. new treatments better-tolerated have shown success rates more than 95%. However, recent breakthrough raises questions challenges, including identification HCV-infected link them appropriate health care, high pricing drugs, emergence resistance or naturally occurring polymorphism sequences compromise response. Finally, we still do not vaccine HCV. In this concise review, will highlight We focus on most significant unsolved problems key future challenges management